New findings from the Women’s Health Initiative trials provide long-term insights into the effects of hormone therapy regimens on ovarian and endometrial cancer incidence and mortality.
A large multicenter study suggests that artificial intelligence-supported mammography screening can improve breast cancer detection rates without increasing recall rates, addressing key challenges in...
A recent study assessed cervical cancer mortality trends among US women younger than 25 from 1992 to 2021, highlighting changes in mortality rates following the widespread use of the HPV vaccine.
Researchers developed a cross-sectional survey to understand the public and provider awareness of postmenopausal bleeding as a symptom of endometrial cancer.
A decade-long follow-up of a landmark trial examining survival outcomes in patients with advanced melanoma treated with nivolumab plus ipilimumab, nivolumab monotherapy, or ipilimumab monotherapy, provides...
A recent phase 3 study found that venetoclax-obinutuzumab improves progression-free survival and quality of life compared with chlorambucil-obinutuzumab in patients with untreated chronic lymphocytic...
A recent phase 3 trial demonstrated that a personalized approach using ibrutinib-venetoclax therapy, based on measurable residual disease, improves progression-free survival and overall survival in patients...
A new retrospective study examines treatment trends among men with limited life expectancy diagnosed with prostate cancer in the Veterans Affairs health system from 2000 to 2019. Researchers explored...
Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
